首页
催化受体
细胞因子受体家族
Sarilumab (anti-IL-6Rα), 白细胞介素-6 受体 α 亚基抗体

Sarilumab (anti-IL-6Rα), 白细胞介素-6 受体 α 亚基抗体

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
S412003-100μg	100μg	现货
S412003-1mg	1mg	现货
S412003-5mg	5mg	现货
S412003-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: IL6R

Accession#:P08887 (9) Gene ID:3570 (9) IL6R (10) Interleukin-6 receptor，α subunit Antibody (1)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Sarilumab (anti-IL-6Rα), 白细胞介素-6 受体 α 亚基抗体
别名	沙利单抗(抗 IL-6Rα)
英文别名	gp80 \| IL-6 receptor subunit alpha \| IL-6R 1 \| IL-6R subunit alpha \| IL-6RA \| IL-6R-alpha \| Membrane glycoprotein 80
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	IL6R
应用	Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	拮抗剂
作用机制	白细胞介素-6 受体 α 亚基抗体

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	27.0 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 186.5 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1189541-98-7
分子类型	抗体

关联靶点（人）

IL6R Tclin 白细胞介素-6 受体亚基 α(Interleukin-6 receptor subunit alpha) (0 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

IL6R Tclin Interleukin-6 receptor alpha subunit (0 活性数据)

点击查看靶蛋白信息： IL6R

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Sarilumab (anti-IL-6Rα) (S412003)

Sarilumab (anti-IL-6Rα) (S412003) - Flow Cytometry
Flow Cytometry analysis of U937 cells labelling IL-6Rα (red) with Sarilumab (anti-IL-6Rα) (S412003). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: Sarilumab (anti-IL-6Rα) (S412003)

Sarilumab (anti-IL-6Rα) (S412003) - SEC
The purity of Sarilumab (anti-IL-6Rα) (S412003) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到1个结果

批号(Lot Number)	证书类型	货号
ZJ24F0102631	分析证书	S412003

可替换产品

引用文献

1. Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y et al.. (2017) Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.. RMD Open, 3 (1): (e000416). [PMID:28326189]
2. Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. (2016) Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.. Arthritis Res Ther, 18 (1): (225). [PMID:27716324]
3. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB. (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.. Ann Rheum Dis, 76 (5): (840-847). [PMID:27856432]
4. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M et al.. (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.. Ann Rheum Dis, 79 (10): (1277-1285). [PMID:32620597]
5. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334]
6. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039]
7. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182]
8. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785]
9. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (135). [PMID:25994180]
10. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] [10.1016/j.immuni.2019.03.026]
11. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C.. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.. J Med Chem, 57 (3): (632-641). [PMID:24456369] [10.1021/jm401144z]
12. Schooltink, H H and 7 more authors.. (1991) Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells.. The Biochemical journal, (1): [PMID:1872801]
13. Novick, D D, Engelmann, H H, Wallach, D D and Rubinstein, M M.. (1989) Soluble cytokine receptors are present in normal human urine.. The Journal of experimental medicine, (1): [PMID:2529343]
14. Yamasaki, K K and 8 more authors.. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.. Science (New York, N.Y.), (12): [PMID:3136546]
15. Horiuchi, S S and 8 more authors.. (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.. European journal of immunology, [PMID:8056053]
16. Yawata, H H and 7 more authors.. (1993) Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130.. The EMBO journal, [PMID:8467812]
17. Cole, A R AR and 6 more authors.. (1999) Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.. The Journal of biological chemistry, (12): [PMID:10066782]
18. Martens, A S AS, Bode, J G JG, Heinrich, P C PC and Graeve, L L.. (2000) The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized madin-darby canine kidney cells.. Journal of cell science, [PMID:11017875]
19. Nakahara, Hideko H and 6 more authors.. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.. Arthritis and rheumatism, [PMID:12794819]
20. Buk, Deborah M DM, Renner, Olga O and Graeve, Lutz L.. (2005) Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80.. European journal of cell biology, [PMID:16270750]
21. Gregory, S G SG and 178 more authors.. (2006) The DNA sequence and biological annotation of human chromosome 1.. Nature, (18): [PMID:16710414]
22. Smolen, Josef S JS and Maini, Ravinder N RN.. (2006) Interleukin-6: a new therapeutic target.. Arthritis research & therapy, [PMID:16899109]
23. Reich, David D and 23 more authors.. (2007) Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.. American journal of human genetics, [PMID:17357077]
24. Betts, Brian C BC, St Angelo, Erin T ET, Kennedy, Michael M and Young, James W JW.. (2011) Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.. Blood, (10): [PMID:21940820]
25. Huizinga, Tom W J TW and 9 more authors.. (2014) Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.. Annals of the rheumatic diseases, [PMID:24297381]
26. and Lin, Phoebe P.. (2015) Targeting interleukin-6 for noninfectious uveitis.. Clinical ophthalmology (Auckland, N.Z.), [PMID:26392750]
27. Lokau, Juliane J and 13 more authors.. (2016) Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.. Cell reports, (23): [PMID:26876177]
28. June, Rayford R RR and Olsen, Nancy J NJ.. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.. Expert opinion on biological therapy, [PMID:27464017]
29. Riethmueller, Steffen S and 23 more authors.. (2017) Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.. PLoS biology, [PMID:28060820]
30. Smolen, Josef S JS and 48 more authors.. (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.. Annals of the rheumatic diseases, [PMID:28264816]
31. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003]
32. Kampan, Nirmala Chandralega NC and 5 more authors.. (2018) Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.. Current medicinal chemistry, [PMID:28707587]
33. Spencer, Sarah and 37 more authors.. (2019) Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.. The Journal of experimental medicine, (2): [PMID:31235509]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Sarilumab (anti-IL-6Rα), 白细胞介素-6 受体 α 亚基抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器